TY - JOUR
T1 - Total body irradiation and risk of breast cancer after blood or marrow transplantation
T2 - A blood or marrow transplantation survivor study report
AU - McDonald, Andrew M.
AU - Chen, Yanjun
AU - Wu, Jessica
AU - Hageman, Lindsey
AU - Francisco, Liton
AU - Kung, Michelle
AU - Wong, F. Lennie
AU - Ness, Emily
AU - Landier, Wendy
AU - Battles, Kevin
AU - Salzman, Donna
AU - Weisdorf, Daniel J.
AU - Forman, Stephen J.
AU - Arora, Mukta
AU - Armenian, Saro H.
AU - Bhatia, Smita
N1 - Funding Information:
Supported in part by grants from the National Cancer Institute (R01 CA078938 and U01 CA213140) and the Leukemia Lymphoma Society (R6502-16).
Publisher Copyright:
© 2020 by American Society of Clinical Oncology.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - PURPOSE: To examine the association between total body irradiation (TBI) and subsequent breast cancer in women treated with blood or marrow transplantation (BMT) for hematologic malignancies.PATIENTS AND METHODS: Participants were drawn from the BMT Survivor Study (BMTSS), a retrospective cohort study that included patients who underwent transplantation between 1974 and 2014 and survived for ≥ 2 years after BMT. Patients with pre-BMT chest radiation or a history of breast cancer were excluded. Participants completed the BMTSS survey, which included details regarding breast cancer diagnosis. Subsequent breast cancer was confirmed by pathology report review or physician notes. Cox proportional hazards models assessed the association between TBI and subsequent breast cancer. Standardized incidence ratios were calculated to determine the excess risk of subsequent breast cancer compared with that in the general population.RESULTS: A total of 1,464 female BMT survivors (allogeneic: n = 788; autologous: n = 676) participated, with a median follow-up of 9.3 years from BMT. TBI was used in 660 patients (46%). Thirty-seven women developed subsequent breast cancer (allogeneic: n = 19; autologous: n = 18). Multivariable analysis revealed that exposure to TBI was associated with an increased risk of subsequent breast cancer among allogeneic BMT survivors (hazard ratio [HR], 3.7 [95% CI, 1.2 to 11.8];
P = .03) and autologous BMT survivors (HR, 2.6 [95% CI, 1.0 to 6.8];
P = .048). Pre-BMT exposure to alkylating agents was associated with an increased risk of subsequent breast cancer among autologous BMT survivors (HR, 3.3 [95% CI, 1.0 to 9.0];
P = .05). Compared with that in the general population, exposure to TBI at age < 30 years was associated with a 4.4-fold higher risk of subsequent breast cancer in allogeneic BMT survivors and a 4.6-fold higher risk in autologous BMT survivors.
CONCLUSION: The association between TBI and subsequent breast cancer, especially among those exposed at a young age, as well as pre-BMT exposure to alkylating agents, should inform breast cancer screening for early detection.
AB - PURPOSE: To examine the association between total body irradiation (TBI) and subsequent breast cancer in women treated with blood or marrow transplantation (BMT) for hematologic malignancies.PATIENTS AND METHODS: Participants were drawn from the BMT Survivor Study (BMTSS), a retrospective cohort study that included patients who underwent transplantation between 1974 and 2014 and survived for ≥ 2 years after BMT. Patients with pre-BMT chest radiation or a history of breast cancer were excluded. Participants completed the BMTSS survey, which included details regarding breast cancer diagnosis. Subsequent breast cancer was confirmed by pathology report review or physician notes. Cox proportional hazards models assessed the association between TBI and subsequent breast cancer. Standardized incidence ratios were calculated to determine the excess risk of subsequent breast cancer compared with that in the general population.RESULTS: A total of 1,464 female BMT survivors (allogeneic: n = 788; autologous: n = 676) participated, with a median follow-up of 9.3 years from BMT. TBI was used in 660 patients (46%). Thirty-seven women developed subsequent breast cancer (allogeneic: n = 19; autologous: n = 18). Multivariable analysis revealed that exposure to TBI was associated with an increased risk of subsequent breast cancer among allogeneic BMT survivors (hazard ratio [HR], 3.7 [95% CI, 1.2 to 11.8];
P = .03) and autologous BMT survivors (HR, 2.6 [95% CI, 1.0 to 6.8];
P = .048). Pre-BMT exposure to alkylating agents was associated with an increased risk of subsequent breast cancer among autologous BMT survivors (HR, 3.3 [95% CI, 1.0 to 9.0];
P = .05). Compared with that in the general population, exposure to TBI at age < 30 years was associated with a 4.4-fold higher risk of subsequent breast cancer in allogeneic BMT survivors and a 4.6-fold higher risk in autologous BMT survivors.
CONCLUSION: The association between TBI and subsequent breast cancer, especially among those exposed at a young age, as well as pre-BMT exposure to alkylating agents, should inform breast cancer screening for early detection.
UR - http://www.scopus.com/inward/record.url?scp=85090077703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090077703&partnerID=8YFLogxK
U2 - 10.1200/JCO.20.00231
DO - 10.1200/JCO.20.00231
M3 - Article
C2 - 32673169
AN - SCOPUS:85090077703
SN - 0732-183X
VL - 38
SP - 2872
EP - 2882
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 25
ER -
